PMID- 35873543
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220726
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Super-Resolution Quantification of T2DM-Induced Mitochondrial Morphology Changes 
      and Their Implications in Pharmacodynamics of Metformin and Sorafenib.
PG  - 932116
LID - 10.3389/fphar.2022.932116 [doi]
LID - 932116
AB  - Mitochondria, as the powerhouse of cells, are involved in various processes of 
      cellular homeostasis, especially energy metabolism. The morphology of 
      mitochondria is a critical indicator for their functions, referring to 
      mitochondrial fusion and fission. Here, we performed structured illumination 
      microscopy (SIM) to measure the mitochondrial morphology in living cells. 
      Benefitting from its nano-scale resolution, this SIM-based strategy can quantify 
      the fusion and fission of mitochondria with high sensitivity. Furthermore, as 
      type 2 diabetes mellitus (T2DM) is caused by a disorder of energy substrate 
      utilization, this strategy has the potential to study T2DM by analyzing the 
      mitochondrial morphology of insulin-resistant (IR) cells. With SIM, we found that 
      mitochondrial fission was increased in IR MRC-5, LO2, FHs 74 Int, and HepG2 cells 
      but not in IR Huh7 cells with high-invasiveness ability. Furthermore, we found 
      that metformin could inhibit mitochondrial fission in IR cells, and sorafenib 
      could promote mitochondrial fusion in HepG2 cancer cells, especially in those IR 
      cells. To conclude, mitochondrial fission is involved in T2DM, and cancer cells 
      with high-invasiveness ability may be equipped with stronger resistance to energy 
      metabolism disorder. In addition, the pharmacodynamics of metformin and sorafenib 
      in cancer may be related to the inhibition of mitochondrial fission, especially 
      for patients with T2DM.
CI  - Copyright (c) 2022 Du, Zhu, Zeng, Mu and Liu.
FAU - Du, Yang
AU  - Du Y
AD  - Cancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West 
      China Hospital, West China Medical School, Sichuan University, Chengdu, China.
FAU - Zhu, Ya-Juan
AU  - Zhu YJ
AD  - Cancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West 
      China Hospital, West China Medical School, Sichuan University, Chengdu, China.
FAU - Zeng, Bo
AU  - Zeng B
AD  - Dean's Office, West China Hospital, Sichuan University, Chengdu, China.
FAU - Mu, Xiao-Li
AU  - Mu XL
AD  - Cancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West 
      China Hospital, West China Medical School, Sichuan University, Chengdu, China.
FAU - Liu, Ji-Yan
AU  - Liu JY
AD  - Cancer Center, State Key Laboratory of Biotherapy, Department of Biotherapy, West 
      China Hospital, West China Medical School, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
DEP - 20220706
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9298863
OTO - NOTNLM
OT  - T2DM
OT  - metformin
OT  - mitochondria
OT  - sorafenib
OT  - structured illumination microscopy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/26 06:00
MHDA- 2022/07/26 06:01
PMCR- 2022/07/06
CRDT- 2022/07/25 03:37
PHST- 2022/04/29 00:00 [received]
PHST- 2022/06/07 00:00 [accepted]
PHST- 2022/07/25 03:37 [entrez]
PHST- 2022/07/26 06:00 [pubmed]
PHST- 2022/07/26 06:01 [medline]
PHST- 2022/07/06 00:00 [pmc-release]
AID - 932116 [pii]
AID - 10.3389/fphar.2022.932116 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Jul 6;13:932116. doi: 10.3389/fphar.2022.932116. 
      eCollection 2022.